Diabetic retinopathy
Conditions
Interventions
Group 2:intravitreal conbercept(IVC) injection
Group 1:intravitreal ranibizumab(IVR) injection
Sponsors
The Fourth Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
5 Years to 100 Years
Inclusion criteria
Inclusion criteria: Patients who had PPV because of PDR, patients who had intravitreal conbercept(IVC) injection and patients who had intravitreal ranibizumab(IVR) injection 3-7d before surgery (rather than other anti-VEGF drgs), and patients who were followed up for at least 3 months.
Exclusion criteria
Exclusion criteria: Previous vitreoretinal surgery, patients with IVC injectiong>1wk before the surgery, neovascular glaucoma, known coagulation abnormalities or current use of anticoagulant or antiplatelet therapy that had high bleeding risk, and additional vitreretinal pathologies such as retinal detachment, uveities, and retinal artery or vein occlusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VEGFR2; | — |
Countries
China
Contacts
Public ContactMa Liwei
The Fourth Hospital of China Medical University
Outcome results
None listed